comprehensive -WSS

comprehensive

author：focus 2025-10-01 04:12:17 - browse：53

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Medicare Advantage enrollment hits roughly 33.4 million

WSS

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

FDA warns medical device makers about rise in fabricated data

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Surprise medical billing ban raises prices elsewhere

Medicare’s new pay boost for primary care is angering specialists

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

explore

comprehensive

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Medicare proposal to cover medical devices draws a mixed reaction

Congress may force more Covid

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Psychedelics group wrestles with new pharma identity

Type 2 diabetes prevention programs work at large scale: study

Walensky prepares to leave CDC — and Congress — behind

As AI regulations shape up, health tech startups beg for clarity

leisure time

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

White House drug czar issues call for 'recovery

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Measles policy set amid Florida outbreak alarms vaccine proponents

Ukraine seeks to reclaim its role as a hub for clinical trials

What health policies could hitch a ride on a spending bill?

hotspot

leisure time

focus

leisure time